| The work identifies KLF4 as a putative tumor suppressor in B-cell malignancies. | None |
| Notch inhibits expression of the Kr??ppel-like factor 4 tumor suppressor in the intestinal epithelium. | None |
| KLF4 may function as a tumor suppressor gene in urothelial cancer since down-regulation of KLF4 by promoter hypermethylation would promote cancer progression. | None |
| findings demonstrate that KLF4 acts as a tumor suppressor in PDAC cells that restricts metastatic behaviors through direct negative regulation of CD44, providing support for the clinical investigation of therapeutic approaches focusing on targeted KLF4 activation in advanced tumors | None |
| MiR-375 is possibly a tumor suppressor in LSCC by regulating KLF4. | None |
| KLF4 is downregulated in anaplastic meningioma compared with low-grade meningioma subtypes. By manipulating KLF4 expression in anaplastic meningioma stem-like cells, this study demonstrated that KLF4 acts as a tumor suppressor during malignant progression in meningioma, affecting apoptosis, proliferation, invasion, and cell cycle. | None |
| The findings suggest that in Klf4-null cells, decreased Bnip3 expression impairs mitophagy and is associated with increased mitochondrial ROS production after mitochondrial damage, providing a rationale for their genomic instability and supports a tumor suppressive role for KLF4 in certain tumors as previously observed. | None |
| Kruppel-like factor 4 acts as an oncogene in colon cancer stem cell-enriched spheroid cells. | colorectal, |
| KLF4 may play an anti-oncogenic role in gastric tumorigenesis. | gastric, |
| KLF4 might play Janus-faced roles in oral squamous cell carcinoma, acting both as a tumor suppressor and as an oncogene. | oral |
| KLF4 suppresses oncogenic TGF-beta signaling by activation of Smad7 transcription, and loss of KLF4 expression in primary hepatocellular carcinoma may contribute to activation of oncogenic TGF-beta signaling and subsequent tumor progression. | liver, |
| our results lead us to propose a model where elevated KLF4 levels sustains the oncogenic state of Head and neck squamous cell carcinoma by reactivating repressed chromatin domains at key downstream genes, often by targeting super-enhancers. | HNSC, |
| The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. | None |
| These results unmask KLF4 as a regulator of p53 that oncogenically transforms cells as a function of p21CIP1 status. | None |
| KLF4 pathway is a potential effector of retinoid signaling in tumor prevention. Of several oncogenes that independently induce malignant transformation of RK3E epithelial cells, only KLF4 showed substantial sensitivity to retinoids. | None |
| study provides evidence that KLF4 has a potent oncogenic role in mammary tumorigenesis likely by maintaining stem cell-like features and by promoting cell migration and invasion | None |
| BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4. | None |
| MicroRNA Replacing Oncogenic Klf4 and c-Myc for Generating iPS Cells via Cationized Pleurotus eryngii Polysaccharide-based Nanotransfection. | None |